step semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the Trials 1 to 5 - Kushner - 2020 - Obesity Semaglutide: The Drug of Today

Learn more about our broader weight management options on our medical weight loss services page, or browse evidence-based articles on GLP-1 therapy on our blog

Heres the truth: Body Composition Kit is not a weight-loss program

A February 2026 peer-reviewed study (Kasher Meron et al.) found an 11% higher fragility fracture risk in GLP-1 users aged 65+ with Type 2 diabetes versus those on other diabetes medications - a retrospective study showing association, not proven causation

[DOI] [PMC free article] [PubMed] [Google Scholar] 98.Braca S., Russo C.V., Stornaiuolo A., Cretella G., Miele A., Giannini C., De Simone R

[DOI] [PubMed] [Google Scholar] 43.Corbin KD, Carnero EA, Allerton TD, Tillner J, Bock CP, Luyet PP, et al

Mais celles-ci crent aussi des dpendances et provoquent des effets secondaires dangereux, comme une acclration du rythme cardiaque, de l'hypertension et de l'hyperthermie